A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Bioasis Technologies Inc (CVE:BTI) (OTCQB:BIOAF) has announced the publication of research validating the ability of its xB3 platform to cross the intact blood-brain barrier (BBB) and its localization in a variety of brain cell types. The company said research shows that the xB3 platform can cross intact BBB and enter intracellular organelles within neurons, glia and microglia in the brain. It said the data from a study published on June 2 in the Frontiers in Neuroscience provide evidence for the utility of xB3 peptide (previously known as MTfpep) as a platform technology for delivery of recombinant and chemically conjugated drug across the BBB.
MedX Health Corp. Announces First Quarter 2021 Results streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.